Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKTivate imaging trial of capivasertib with or without exemestane in early ER-positive HER2-negative breast cancer
ISRCTN99425493Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of capivasertib and exemestane in breast cancer (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Target engagement detected by hyperpolarized 13C MRSI and Reduction in hyperpolarized lactate/pyruvate ratio. Started Oct 2025; status: terminated.
02
Drugs
capivasertibexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN99425493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99425493.